Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No "Statistical Alchemy" Here: Meta-Analyses Can Reduce Trial Size

Executive Summary

Hints about the direction FDA's Meta-Analysis Working Group may take in drafting guidance, and the Institute of Medicine may adopt in twin reports on the subject, can be found in journal articles by Joseph Lau, a professor of medicine at Tufts who is involved in all three efforts (see 1preceding story)

You may also be interested in...



Meta-Analyses Will Get Separate Guidance Documents From FDA And IoM

The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel